Clinical Trial Update: Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of HIV vaccines (Env/Gag DNA and gp120 protein/GLA-SE), given alone or co-administered, in healthy HIV-uninfe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV vaccines

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2022-04-25